➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
AstraZeneca
McKesson
Express Scripts
Mallinckrodt

Last Updated: October 25, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for SD-809

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for SD-809?

SD-809 is an investigational drug.

There have been 9 clinical trials for SD-809. The most recent clinical trial was a Phase 3 trial, which was initiated on June 22nd 2018.

The most common disease conditions in clinical trials are Dyskinesias, Movement Disorders, and Tourette Syndrome. The leading clinical trial sponsors are Auspex Pharmaceuticals, Inc., Teva Branded Pharmaceutical Products, R&D Inc., and Nuvelution TS Pharma, Inc.

There are six US patents protecting this investigational drug and forty-eight international patents.

Recent Clinical Trials for SD-809
TitleSponsorPhase
A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral PalsyTeva Branded Pharmaceutical Products, R&D Inc.Phase 3
A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and AdolescentsTeva Branded Pharmaceutical Products, R&D Inc.Phase 3
A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette SyndromeNuvelution TS Pharma, Inc.Phase 3

See all SD-809 clinical trials

Clinical Trial Summary for SD-809

Top disease conditions for SD-809
Top clinical trial sponsors for SD-809

See all SD-809 clinical trials

US Patents for SD-809

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
SD-809   Start Trial Benzoquinoline inhibitors of vesicular monoamine transporter 2 Auspex Pharmaceuticals (La Jolla, CA)   Start Trial
SD-809   Start Trial Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Auspex Pharmaceuticals, Inc. (La Jolla, CA)   Start Trial
SD-809   Start Trial Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Auspex Pharmaceuticals, Inc. (La Jolla, CA)   Start Trial
SD-809   Start Trial Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Auspex Pharmaceuticals, Inc. (La Jolla, CA)   Start Trial
SD-809   Start Trial Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Auspex Pharmaceuticals, Inc. (LaJolla, CA)   Start Trial
SD-809   Start Trial Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Auspex Pharmaceuticals, Inc. (Frazer, PA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for SD-809

Drugname Country Document Number Estimated Expiration Related US Patent
SD-809 Australia 2009303758 2028-09-18   Start Trial
SD-809 Canada 2736409 2028-09-18   Start Trial
SD-809 Canada 2972242 2028-09-18   Start Trial
SD-809 China 102186848 2028-09-18   Start Trial
SD-809 China 104311552 2028-09-18   Start Trial
SD-809 Cyprus 1120060 2028-09-18   Start Trial
SD-809 Denmark 2326643 2028-09-18   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
AstraZeneca
McKesson
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.